JP2017536363A - リソソーム蓄積症治療のための組成物及び方法 - Google Patents

リソソーム蓄積症治療のための組成物及び方法 Download PDF

Info

Publication number
JP2017536363A
JP2017536363A JP2017526853A JP2017526853A JP2017536363A JP 2017536363 A JP2017536363 A JP 2017536363A JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017536363 A JP2017536363 A JP 2017536363A
Authority
JP
Japan
Prior art keywords
disease
tfeb
pparα
aspirin
fibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536363A5 (enExample
Inventor
パハン，カリパダ
Original Assignee
ラッシュ・ユニバーシティ・メディカル・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラッシュ・ユニバーシティ・メディカル・センター filed Critical ラッシュ・ユニバーシティ・メディカル・センター
Publication of JP2017536363A publication Critical patent/JP2017536363A/ja
Publication of JP2017536363A5 publication Critical patent/JP2017536363A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017526853A 2014-11-19 2015-11-16 リソソーム蓄積症治療のための組成物及び方法 Pending JP2017536363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081696P 2014-11-19 2014-11-19
US62/081,696 2014-11-19
PCT/US2015/060878 WO2016081365A1 (en) 2014-11-19 2015-11-16 Compositions and methods for treating lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019232644A Division JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2017536363A true JP2017536363A (ja) 2017-12-07
JP2017536363A5 JP2017536363A5 (enExample) 2018-10-18

Family

ID=56014423

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017526853A Pending JP2017536363A (ja) 2014-11-19 2015-11-16 リソソーム蓄積症治療のための組成物及び方法
JP2019232644A Pending JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法
JP2021063971A Active JP7752958B2 (ja) 2014-11-19 2021-04-05 リソソーム蓄積症治療のための組成物及び方法
JP2021153206A Withdrawn JP2022003060A (ja) 2014-11-19 2021-09-21 リソソーム蓄積症治療のための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019232644A Pending JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法
JP2021063971A Active JP7752958B2 (ja) 2014-11-19 2021-04-05 リソソーム蓄積症治療のための組成物及び方法
JP2021153206A Withdrawn JP2022003060A (ja) 2014-11-19 2021-09-21 リソソーム蓄積症治療のための組成物及び方法

Country Status (9)

Country Link
US (3) US20170354666A1 (enExample)
EP (2) EP4026545A1 (enExample)
JP (4) JP2017536363A (enExample)
KR (1) KR20170083146A (enExample)
CN (1) CN107205976A (enExample)
AU (1) AU2015350223B2 (enExample)
CA (2) CA3176253A1 (enExample)
ES (1) ES2914085T3 (enExample)
WO (1) WO2016081365A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019156252A1 (ja) * 2018-02-06 2019-08-15 国立大学法人京都大学 ライソゾーム病の予防及び治療剤
JP2022516631A (ja) * 2019-01-03 2022-03-01 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料
JP2022525888A (ja) * 2019-03-22 2022-05-20 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症のための、経鼻遺伝子送達と経口の桂皮酸、オレアミド、またはゲムフィブロジルとの組合せ

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493023B2 (en) 2013-05-07 2019-12-03 Seelos Therapeutics, Inc. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
CA3176253A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Use of cinnamic acid or sodium benzoate for treating lysosomal disorders
CN109563024B (zh) 2016-06-13 2023-06-06 心悦生医股份有限公司 苯甲酸锂的共晶及其用途
CN109563018A (zh) * 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸钠的共晶及其用途
US11020366B2 (en) * 2016-12-29 2021-06-01 Rush University Medical Center Locomotor activity and increase in longevity of late infantile neuronal ceriod lipofuscinosis subjects by Gemfibrozil
JP6991246B2 (ja) * 2017-02-08 2022-02-03 ノバルティス アーゲー Ｆｇｆ２１模倣抗体及びその使用
WO2019152391A1 (en) * 2018-01-30 2019-08-08 Rush University Medical Center Sequential staining for multiplex analyses of tissues and cells
US20210186937A1 (en) * 2018-05-22 2021-06-24 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
EP3876932A4 (en) * 2018-11-05 2022-07-20 Rush University Medical Center Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases
EA202192199A1 (ru) * 2019-02-25 2021-12-17 Раш Юниверсити Медикал Сентер Композиции, содержащие коричную кислоту, и способы их применения
CA3153963A1 (en) * 2019-09-09 2021-03-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb
WO2021067243A1 (en) * 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
WO2022159086A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease
EP4447952A4 (en) * 2021-12-16 2025-11-19 Us Gov Veterans Affairs Benzoic acid salts for the treatment of injuries and disorders of the nervous system
US12042476B2 (en) * 2022-02-04 2024-07-23 Mcmaster University Methods for the treatment of lysosomal storage diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040816A1 (en) * 2007-09-26 2009-04-02 Ramot At Tel Aviv University Ltd. Methods of treating lysosomal storage disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311356C (en) 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US20010028895A1 (en) 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
KR101573316B1 (ko) * 2004-03-29 2015-12-01 와이어쓰 엘엘씨 종합비타민 및 무기물 영양 보충제
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
ES2246737B1 (es) * 2005-06-09 2006-12-01 Jose Juan Rodriguez Jerez "composicion farmaceutica que comprende lisina y usos correspondientes".
JP2009084155A (ja) * 2006-01-16 2009-04-23 Kanazawa Univ レビー小体病治療薬及びレビー小体病予防薬
US20070225360A1 (en) * 2006-03-22 2007-09-27 L'oreal Anti-aging composition containing phloretin
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US9388413B2 (en) * 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US9388414B2 (en) * 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
JP2010106001A (ja) 2008-10-31 2010-05-13 Theravalues Corp Ｐｐａｒ活性化剤
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
MX337933B (es) * 2009-10-19 2016-03-29 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
US9845327B2 (en) * 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
PL399467A1 (pl) * 2012-06-08 2013-12-09 3G Therapeutics Inc. Zastosowanie genisteiny do obnizania poziomu zwiazków organicznych spichrzanych w komórkach w leczeniu i/lub zapobieganiu lizosomalnych chorób spichrzeniowych (LChS)
US9750712B2 (en) 2012-12-07 2017-09-05 Rush University Medical Center Composition and method for treating neuronal ceroid lipofuscinosis
CA3176253A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Use of cinnamic acid or sodium benzoate for treating lysosomal disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040816A1 (en) * 2007-09-26 2009-04-02 Ramot At Tel Aviv University Ltd. Methods of treating lysosomal storage disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEVELOPMENTAL CELL, 2011, VOL.21, PP.421-430, JPN6019023518, ISSN: 0004224940 *
J. BIOL. CHEM., 2014.04, VOL.289, NO.14, PP.10211-10222, JPN6019023516, ISSN: 0004224939 *
MEDICAL HYPOTHESES, 2007, VOL.68, NO.4, PP.913, JPN6019023520, ISSN: 0004224941 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019156252A1 (ja) * 2018-02-06 2019-08-15 国立大学法人京都大学 ライソゾーム病の予防及び治療剤
JPWO2019156252A1 (ja) * 2018-02-06 2021-01-28 国立大学法人京都大学 ライソゾーム病の予防及び治療剤
JP7366408B2 (ja) 2018-02-06 2023-10-23 国立大学法人京都大学 ライソゾーム病の予防及び治療剤
JP2022516631A (ja) * 2019-01-03 2022-03-01 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料
JP7566753B2 (ja) 2019-01-03 2024-10-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料
US12286442B2 (en) 2019-01-03 2025-04-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and materials for increasing transcription factor eb polypeptide levels
JP2022525888A (ja) * 2019-03-22 2022-05-20 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症のための、経鼻遺伝子送達と経口の桂皮酸、オレアミド、またはゲムフィブロジルとの組合せ

Also Published As

Publication number Publication date
AU2015350223B2 (en) 2021-04-01
CA2967066A1 (en) 2016-05-26
US12023345B2 (en) 2024-07-02
CN107205976A (zh) 2017-09-26
EP4026545A1 (en) 2022-07-13
US20250134911A1 (en) 2025-05-01
JP7752958B2 (ja) 2025-10-14
JP2022003060A (ja) 2022-01-11
WO2016081365A1 (en) 2016-05-26
US20170354666A1 (en) 2017-12-14
ES2914085T3 (es) 2022-06-07
JP2020100621A (ja) 2020-07-02
JP2021107404A (ja) 2021-07-29
EP3220906B1 (en) 2022-03-02
CA3176253A1 (en) 2016-05-26
EP3220906A4 (en) 2018-04-25
AU2015350223A1 (en) 2017-05-11
EP3220906A1 (en) 2017-09-27
US20230037062A1 (en) 2023-02-02
KR20170083146A (ko) 2017-07-17

Similar Documents

Publication Publication Date Title
JP7752958B2 (ja) リソソーム蓄積症治療のための組成物及び方法
Chinnici et al. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old
US11351142B2 (en) Composition and method for treating neuronal ceroid lipofuscinosis
Ghosh et al. Activation of peroxisome proliferator-activated receptor α induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders
US20180217163A1 (en) Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2012142039A1 (en) Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
Zheng et al. Paroxetine attenuates chondrocyte pyroptosis and inhibits osteoclast formation by inhibiting NF-κB pathway activation to delay osteoarthritis progression
Jiang et al. Icariin ameliorates amyloid pathologies by maintaining homeostasis of autophagic systems in Aβ1–42-injected rats
Bruno et al. Sphingosine 1-phosphate signaling axis mediates fibroblast growth factor 2-induced proliferation and survival of murine auditory neuroblasts
Gong et al. Baicalein promotes the microglia M2 polarization and suppresses apoptosis by targeting HMOX1/PDE4D to alleviate Alzheimer’s disease
Carbone et al. Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP
US11844767B2 (en) Composition and methods for stimulating clearance of amyloid-beta protein
US20060009520A1 (en) Retinoid-based methods for altering macrophage cholesterol
HK40077677A (en) Compositions and methods for treating lysosomal disorders
US8343915B2 (en) Use of heat-shock protein 27 for cardiovascular disease prevention and treatment
LAAVOLA Immunomodulatory Properties of Wood Biochemicals
Lund Regulation of the GABA (A) receptor alpha1 subunit in an animal model of temporal lobe epilepsy
TW201422226A (zh) ＰＰＡＲα活化劑增加ＡＴＧＬ蛋白表現及減少脂肪堆積之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170727

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303